Novo Nordisk and TetraScience have announced a new partnership to design a cloud-based instrument data platform for drug R&D, built natively on Amazon Web Services.
Novo Nordisk will leverage the TetraScience Platform for automated instrument data acquisition and scalable in-cloud processing from heterogeneous sources and data streams, including plate readers, robotic systems, HPLCs, mass spectrometers, flow cytometers, and many more, resulting in harmonized data accessible for exploration, visualization, and advanced data science.
"In order to increase data capture and improve data workflows in early Research, we embarked on this partnership to build up automated structured data pipelines from our laboratory instruments," said Allan Shaw, Corporate Vice President, Computational Research, Novo Nordisk.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
"We are thrilled to collaborate with Novo Nordisk on this new platform," said Spin Wang, President and CTO of TetraScience. "This partnership will further accelerate the velocity of innovation through advanced data exploration. Novo Nordisk is a leader in the realm of human health and by working together to improve and streamline insights gleaned from data, new technologies for drug delivery will be discovered."
"Biopharma R&D needs to unify and harmonize R&D data in the cloud, in order to fully capitalize on the power of AI and data science. In turn, AI and data science will uncover insights that will accelerate the R&D of therapeutics that extend and enhance human life," said Patrick Grady, CEO of TetraScience. "Industry participants of all kinds – global pharmas, biotech startups, informatics applications, contract research organizations, and more – recognize that this movement to the R&D Data Cloud must be driven by an open partner network that is deeply data-centric. We are thrilled to further extend this network together with Novo Nordisk."